Benitec Biopharma (BNTC) Liabilities and Shareholders Equity (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $105.2 million as the latest value for Q1 2025.
- Quarterly Liabilities and Shareholders Equity rose 601.44% to $105.2 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $253.1 million through Jun 2025, up 118.87% year-over-year, with the annual reading at $52.2 million for FY2024, 1069.58% up from the prior year.
- Liabilities and Shareholders Equity hit $105.2 million in Q1 2025 for Benitec Biopharma, up from $79.1 million in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $105.2 million in Q1 2025 to a low of $4.5 million in Q2 2023.
- Historically, Liabilities and Shareholders Equity has averaged $29.1 million across 5 years, with a median of $17.8 million in 2021.
- Biggest five-year swings in Liabilities and Shareholders Equity: crashed 72.06% in 2022 and later surged 1069.58% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $14.0 million in 2021, then decreased by 15.05% to $11.9 million in 2022, then surged by 79.36% to $21.4 million in 2023, then skyrocketed by 270.29% to $79.1 million in 2024, then skyrocketed by 33.06% to $105.2 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for BNTC at $105.2 million in Q1 2025, $79.1 million in Q4 2024, and $68.8 million in Q3 2024.